mRNA vaccines combine desirable immunological properties with an outstanding safety
profile and the unmet flexibility of genetic vaccines. Based on in situ protein expression,
mRNA vaccines are capable of inducing a balanced immune response comprising both …

mRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells.
mRNA vaccines are currently evaluated in clinical trials for cancer immunotherapy
applications, but also have great potential as prophylactic vaccines. Efficient delivery of …

Synthetic mRNAs can become biopharmaceutics allowing vaccination against cancer,
bacterial and virus infections. Clinical trials with direct administration of synthetic mRNAs
encoding tumor antigens demonstrated safety and induction of tumor-specific immune …

Among currently available vaccine strategies for cancer, nucleotide-based vaccination is an
appealing treatment modality. Curevacs' mRNA containing vaccines (RNActive®) combine
the beneficial properties of sufficient antigen-expression, autologous immune-stimulation …

Powassan virus (POWV) is an emerging tick-transmitted flavivirus that circulates in North
America and Russia. Up to 5% of deer ticks now test positive for POWV in certain regions of
the northern United States. Although POWV infections cause life-threatening encephalitis …

We reported a preclinical cancer vaccine that simultaneously introduced an mRNA antigen
and an immune checkpoint blocking siRNA into the antigen-presenting cells. This was
achieved by formulating both nucleic acid-based immunotherapeutics into a lipid-coated …

Prophylactic and therapeutic vaccines often depend upon a strong activation of the innate
immune system to drive a potent adaptive immune response, often mediated by a strong
adjuvant. For a number of adjuvants immunological readouts may not be consistent across …

Here, Pardi and colleagues discuss recent advances in mRNA vaccine technology,
assess mRNA vaccines currently in development for cancer and infectious diseases
and consider future directions and challenges. mRNA …

Triple negative breast cancer (TNBC), which constitutes 10%–20% of all breast cancers, is
associated with aggressive progression, a high rate of metastasis, and poor prognosis. The
treatment of patients with TNBC remains a great clinical challenge. Preclinical reports …

Immunization with mRNA encoding tumor antigen is an emerging vaccine strategy for
cancer. In this paper, we demonstrate that mice receiving systemic injections of MART1
mRNA histidylated lipopolyplexes were specifically and significantly protected against …